SCHEMBL6645067

SCHEMBL6645067

CCc1ccc(-c2ncccc2C(=O)Nc2ccc(NCCn3cccn3)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 8/20 0.46
▸ NPC1 O15118 5/20 0.46
▸ RAB9A P51151 5/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ KLF5 Q13887 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ THRB P10828 1/20 0.44
▸ MAPK13 O15264 1/20 0.43
▸ LIMK1 P53667 1/20 0.43
▸ MARK2 Q7KZI7 1/20 0.43
▸ MAPT P10636 4/20 0.43
▸ TP53 P04637 3/20 0.43
▸ GAA P10253 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.42
▸ TRPV1 Q8NER1 1/20 0.41
▸ PDPK1 O15530 1/20 0.41
▸ HPGD P15428 2/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ NFKB2 Q00653 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6644663 0.91 TRPV1 (0.49) SMN1; SMN2NPC1RAB9ATHRBMAPT
SCHEMBL6647425 0.86 SMN1; SMN2 (0.50) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL6642238 0.84 SMN1; SMN2 (0.43) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL6643623 0.78 SMN1; SMN2 (0.44) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL6644841 0.77 ALDH1A1 (0.46) SMN1; SMN2NPC1RAB9AKMT2ATHRB
SCHEMBL6644186 0.76 TRPV1 (0.45) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL6644882 0.76 THRB (0.46) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL6646034 0.74 APOB (0.48) SMN1; SMN2MAPTGAAALDH1A1TRPV1
SCHEMBL7195954 0.72 L3MBTL1 (0.44) SMN1; SMN2NPC1RAB9ATHRBMAPT
SCHEMBL6646120 0.71 THRB (0.43) MEN1KMT2ATHRBALDH1A1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 — — US disclosed
WO-2004039795-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR SMN1; SMN2 1836/4885NPC1 34/4885RAB9A 3028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback